Skip to main content
. 2024 Aug 21;30(20):4755–4767. doi: 10.1158/1078-0432.CCR-24-0729

Figure 3.

Figure 3.

Pretreatment low CD3+, high KIR2DL2/DL3+NKs, PD1+Tregs and Helios+Tregs predict nivolumab response. A, Frequencies of CD3+ (as a percentage of lymphocytes) and KIR2DL2/DL3+NKs, PD1+Tregs, and Helios+Tregs in R vs. NR patients. CD3+: (33 R vs. 31 NR; P < 0.05); KIR2DL2/DL3+NKs: (28 R vs. 21 NR; P < 0.01); PD1+Tregs: (28 vs. 21 NR; P < 0.05); Helios+Tregs: (24 R vs. 17 NR; P < 0.01). Box plot showing the data distribution across groups with minimum, median, and maximum values. Two-tailed test comparison of differences between two independent groups (*, P < 0.05; **, P < 0.01; ***, P < 0.001). B, Kaplan–Meier survival curves for PFS and OS of patients with mRCC-REV, stratified according to optimal cutoff identified by ROC analyses; C, Kaplan–Meier plots for PFS according to combination of Helios+Tregs-KIR2DL2/DL3+NKs values. Low–Low (black line); Low–High (dotted red line); High–Low (red line); High–High (blue line). P-values by log-rank test.